FX-322-208 Study Fails to Meet Primary Endpoint, Showing No Significant Separation in Speech Perception Between FX-322 and Placebo
Company Will Now Focus on Advancing its Program in Remyelination for Multiple Sclerosis (MS)
Announces Corporate Restructuring and Will Also Explore Strategic Financing Alternatives; Net of Debt, has Cash and Marketable Securities of $68.9mm as of December 31, 2022
https://finance.yahoo.com/news/frequency-therapeutics-announces-topline-results-130500334.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.